Esco Aster vs Exopharm: CDMO Comparison
How does Esco Aster compare to Exopharm for Exosome manufacturing?
Side-by-side comparison of Esco Aster and Exopharm on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
What to evaluate for Exosome programs
Both Esco Aster and Exopharm qualify as Exosome CDMOs. When choosing between them for Exosome programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Cell source & scale
Confirm the producer cell source and whether culture is suspension-adapted for the volumes EV yields demand.
Isolation & purification
Isolation method (tangential-flow filtration, chromatography) drives yield, purity, and scalability. Ask how it performs at your target scale.
Characterization & potency
EV characterization (particle count, size, cargo, identity) and potency assays are still maturing — look for established, qualified methods.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.
Frequently asked: Esco Aster vs Exopharm
How does Esco Aster compare to Exopharm for Exosome manufacturing?
On CDMO Signal's composite Signal Score, Esco Aster is 63/100 and Exopharm is 56/100. Both are tracked in the CDMO Signal directory as Exosome CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which is better for Exosome manufacturing — Esco Aster or Exopharm?
Both Esco Aster and Exopharm are tagged as Exosome CDMOs in our directory, so both are credible options for Exosome programs. The most important differentiator for Exosome selection is typically cell source & scale: Confirm the producer cell source and whether culture is suspension-adapted for the volumes EV yields demand. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
Esco Aster carries a Signal Score of 63/100 and Exopharm carries 56/100 — a small lead for Esco Aster. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →